Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats

Journal of Musculoskeletal Neuronal Interactions

Volumn 3, Issue 2, 2003, Pages 148-155

  Andresen, C ^a   Bagi, Cedo M ^a   Adams, S W ^a  

^a Drug Safety Evaluation   (United States)

Author keywords

Bone formation; Bone resorption; Cancer of the prostate; CWR22; Nude rat; Osteoclerosis; Prostate specific antigen; Testosterone

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LESION; BONE MARROW; BONE MATRIX; BONE METASTASIS; BONE RADIOGRAPHY; CANCER CELL CULTURE; CANCER STAGING; CONTROLLED STUDY; GROWTH RATE; HISTOPATHOLOGY; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION; MALE; MAMMAL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATE CANCER; RAT; RAT STRAIN; STROMA; TIBIA; TUMOR CELL;

EID: 0043244928     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Newling DW. The geography of prostate cancer and its treatment in Europe. Cancer Surv 1995; 23:289-296.
2. Peterson MC. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987; 8(Suppl.):17-22.
3. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem 1992; 16(Suppl.):89-98.
4. Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res 1991; 51:3814-3817.
5. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996; 56:3042-3046.
6. Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors. Prostate 1999; 41:7-11.
7. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, Pretlow TP. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993; 85:394-398.
8. Willmans C, Fan D, O'Brian CA, Bucana CD, Fidler IJ. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxoxrubicin and 5-fluorouracil. Int J Cancer 1992; 52:98-104.
9. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth GHA Clowes memorial award lecture. Cancer Res 1990; 50:6130-6138.
10. Kuo T-H, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H, Nishibori H, Saikawa Y, Ishibiki K, Kitajama M, Hoffman RM. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: The importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res 1993; 13:627-630.
11. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986; 9:961-981.
12. Zhau HE, Li C-L, Chung LWK. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000; 88(Suppl.12):2995-2301.
13. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56:4096-4102.
14. Nemeth JA, Harb JF, Barroso U-Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999; 59:1987-1993.
15. Thalmann HN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach EA, Chung LWK. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54:2577-2581.
16. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer1998; 34:240-245.
17. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LDA. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997; 57:1584-1589.
18. Shevrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in atymic nude mice. Clin Exp Metastasis 1988; 6:401-409.
19. Galasko CSA. Mechanism of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 169:20-27.
20. Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and hypercalcemia in breast cancer. BMJ 1991; 303:1506-1509.
21. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone related protein in breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544-1549.
22. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
23. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876-6881.
24. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term follow-up of two randomized, placebo controlled trials. Cancer 2000; 88:1082-1090.
25. Papapoulos SE, Hamdy NAT, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 2000; 88(Suppl.12):3047-3053.
26. Boissier S, Magneto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894.
27. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Min Res 1999; 14(Suppl.2):56-65.
28. Stenman U-H, Leinonen J, Zhang W-M, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999; 9:83-93.
29. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatment with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst 1986; 77:583-587.
30. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267:1-4.
31. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993; 13:481-486.
32. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998; 78:1219-1223.
33. Orr FW, Lee J, Duivenvoorden WCM, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer 2000; 88(Suppl.12):2912-2918.
34. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Eur J Urol 1985; 57:721-723.
35. Percival RC, Urwin GH, Harris S, Watson ME, McCloskey M, Kanis JA. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13:41-49.
36. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001; 57:611-616.
37. Holen I, Croucher PI, Hamdy PC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62:1619-1623.
38. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 1993; 12:287-2301.
39. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987; 84:2024-2028.
40. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544-1549.
41. Blomme EAG, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone related protein. Prostate 1999; 39:187-197.
42. Martin TJ, Mundy GR. Hypercalcemia of malignancy. In: Martin TJ, Raisz LG (eds) Clinical endocrinology of calcium metabolism. Dekker, New York; 1987:171-199.